Goldman Sachs Group Inc Biomarin Pharmaceutical Inc Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 449,966 shares of BMRN stock, worth $29.8 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
449,966
Previous 559,802 19.62%
Holding current value
$29.8 Million
Previous $46.1 Million 31.37%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$69.02 - $93.84 $7.58 Million - $10.3 Million
-109,836 Reduced 19.62%
449,966 $31.6 Million
Q2 2024

Aug 13, 2024
SELL
$74.43 - $92.22 $9.93 Million - $12.3 Million
-133,422 Reduced 19.25%
559,802 $46.1 Million
Q1 2024

May 15, 2024
SELL
$83.81 - $99.0 $18 Million - $21.2 Million
-214,557 Reduced 23.64%
693,224 $60.5 Million
Q4 2023

Feb 13, 2024
SELL
$76.22 - $98.51 $5.47 Million - $7.07 Million
-71,814 Reduced 7.33%
907,781 $87.5 Million
Q3 2023

May 14, 2024
BUY
$85.07 - $94.48 $6.11 Million - $6.78 Million
71,814 Added 7.91%
979,595 $86.7 Million
Q3 2023

Nov 14, 2023
SELL
$85.07 - $94.48 $38.7 Million - $43 Million
-455,302 Reduced 31.73%
979,595 $86.7 Million
Q2 2023

May 14, 2024
BUY
$86.68 - $100.3 $26.5 Million - $30.7 Million
306,018 Added 27.11%
1,434,897 $124 Million
Q2 2023

Aug 14, 2023
BUY
$86.68 - $100.3 $26.5 Million - $30.7 Million
306,018 Added 27.11%
1,434,897 $124 Million
Q1 2023

May 14, 2024
SELL
$87.74 - $117.27 $3.7 Million - $4.95 Million
-42,172 Reduced 3.6%
1,128,879 $110 Million
Q1 2023

May 11, 2023
SELL
$87.74 - $117.27 $3.7 Million - $4.95 Million
-42,172 Reduced 3.6%
1,128,879 $110 Million
Q4 2022

May 14, 2024
BUY
$80.93 - $108.63 $31.4 Million - $42.2 Million
388,026 Added 49.55%
1,171,051 $121 Million
Q4 2022

Feb 13, 2023
BUY
$80.93 - $108.63 $31.4 Million - $42.2 Million
388,026 Added 49.55%
1,171,051 $121 Million
Q3 2022

May 14, 2024
SELL
$82.16 - $96.94 $3.26 Million - $3.85 Million
-39,673 Reduced 4.82%
783,025 $66.4 Million
Q3 2022

Nov 10, 2022
SELL
$82.16 - $96.94 $3.26 Million - $3.85 Million
-39,673 Reduced 4.82%
783,025 $66.4 Million
Q2 2022

May 14, 2024
SELL
$71.48 - $86.85 $6.08 Million - $7.39 Million
-85,083 Reduced 9.37%
822,698 $68.2 Million
Q2 2022

Aug 15, 2022
BUY
$71.48 - $86.85 $8.15 Million - $9.91 Million
114,080 Added 16.1%
822,698 $68.2 Million
Q1 2022

May 16, 2022
SELL
$74.28 - $92.69 $7.91 Million - $9.87 Million
-106,449 Reduced 13.06%
708,618 $54.6 Million
Q4 2021

Feb 14, 2022
SELL
$71.72 - $91.47 $48.2 Million - $61.4 Million
-671,512 Reduced 45.17%
815,067 $72 Million
Q3 2021

Nov 10, 2021
BUY
$74.77 - $85.47 $111 Million - $127 Million
1,486,579 New
1,486,579 $115 Million

Others Institutions Holding BMRN

# of Institutions
637
Shares Held
177M
Call Options Held
2.01M
Put Options Held
1.28M
View Full List

About BIOMARIN PHARMACEUTICAL INC

BMRN Quotes by TradingView
  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.3B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email